论文部分内容阅读
目的:对中重度慢性阻塞性肺疾病稳定期患者进行研究,探讨噻托溴铵对该疾病的治疗效果。方法:选取我院所收治中重度慢性阻塞性肺疾病稳定期的患者100例,将所有患者进行随机分组,共分为两组,一组为观察组,采用噻托溴铵进行治疗,另一组为对照组,采用异丙托溴铵进行治疗,两组的疗程均为2个月,观察两组患者的症状,以及具体的肺功能改善情况,进行探讨。结果:经过观察,观察组患者的症状以及肺功能改善的情况都比对照组的患者要好,肺功能从治疗前到治疗后,其FEV1以及FVC的值明显有所改善,经统计方法的分析,P<0.05,即两组间的差异具有统计学意义,另外,5例患者在用药以后出现轻微的口干现象,两组患者中,出现该不良反应的患者例数分别为观察组2例,对照组3例。结论:与异丙托溴铵相比,采用噻托溴铵对中重度慢性阻塞性肺疾病稳定期进行治疗有更好的治疗效果,且不良反应很少。
Objective: To study the stability of patients with moderate-severe chronic obstructive pulmonary disease, to explore the effect of tiotropium on the disease. Methods: A total of 100 patients with stable chronic obstructive pulmonary disease (COPD) admitted to our hospital were enrolled in this study. All patients were randomly divided into two groups: one was treated with tiotropium and the other was treated with tiotropium Group as control group, the treatment with ipratropium bromide, two groups of treatment were 2 months, observe the symptoms of the two groups of patients, and specific lung function improvement, to explore. Results: After observation, the symptom of patients in the observation group and the improvement of pulmonary function were better than those in the control group. The FEV1 and FVC values of pulmonary function improved significantly from before treatment to after treatment. After statistical analysis, P <0.05, that is, the difference between the two groups was statistically significant. In addition, 5 patients showed mild dry mouth after treatment. The number of patients with adverse reactions in the two groups were 2 cases in the observation group, Control group of 3 cases. Conclusion: Compared with ipratropium bromide, the use of tiotropium for the treatment of moderate-to-severe chronic obstructive pulmonary disease has a better therapeutic effect, with little adverse reaction.